Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC

Executive Summary

Merck & Co just keeps clearing the hurdles to checkpoint inhibitor market domination, with EU approval in the key first-line NSCLC indication coming swiftly after the company snuck in an earlier than expected filing in the US for its chemo combination use.

You may also be interested in...



Under Fire, Bristol Plans To Pick Up The IO Pieces

Facing analysts jittery about the prospects for Opdivo/Yervoy in first-line lung cancer, Bristol boasts breadth of Phase III lung program, including IO/chemo studies, and variety of tumor types targeted.

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.

AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

With tensions rising in the first-line NSCLC space, AstraZeneca's update on the analysis plan of its Phase III MYSTIC trial has analysts reassessing the firm’s chances against stiff competition.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel